Trials / Completed
CompletedNCT00238732
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
A Double-Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 650 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bazedoxifene/Conjugated Estrogen |
Timeline
- Start date
- 2005-10-01
- Completion
- 2007-03-01
- First posted
- 2005-10-13
- Last updated
- 2007-12-28
Locations
63 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00238732. Inclusion in this directory is not an endorsement.